Reep1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| REEP1 Protein |
|---|
| Protein Name | Receptor Accessory Protein 1 |
| Gene | REEP1 |
| UniProt | Q9H0M0 |
| Molecular Weight | 22 kDa |
| Subcellular Localization | Mitochondria, ER |
| Protein Family | REEP/DP1 family |
| Protein Length | 199 amino acids |
REEP1 (Receptor Accessory Protein 1) is a mitochondrial shaping protein that regulates cristae morphology and axonal mitochondrial distribution. It is mutated in hereditary spastic paraplegia type 31 (SPG31) and Charcot-Marie-Tooth disease type 2. REEP1 belongs to the REEP/DP1 family of proteins that modulate mitochondrial cristae structure and are critical for neuronal mitochondrial function.
REEP1 contains several distinct structural features:
- HPF Domain (Haplophore Domain): Located at the N-terminus, this domain is involved in mitochondrial cristae shaping and forms the characteristic cristae junctions
- Microtubule-Binding Region: Interacts with microtubule-based transport machinery for axonal mitochondrial trafficking
- Transmembrane Domains: Two hydrophobic alpha-helices (TM1 and TM2) that anchor the protein in the mitochondrial inner membrane
- C-terminal Domain: Involved in protein-protein interactions and oligomerization
The protein forms homooligomers that are essential for its function in mitochondrial morphology regulation.
REEP1 functions in multiple cellular processes:
- Shapes mitochondrial cristae and maintains cristae junctions
- Regulates the number and spacing of cristae
- Essential for mitochondrial respiratory function
- Controls mitochondrial DNA nucleoid distribution
- Distributes mitochondria along axons via microtubule interactions
- Maintains synaptic mitochondrial pools
- Supports energy demand at presynaptic terminals
- Critical for axonal viability over long distances
- Regulates membrane contact sites (MCS) between ER and mitochondria
- Facilitates calcium exchange between organelles
- Supports lipid transfer between membranes
- Modulates mitochondrial dynamics
- Maintains mitochondrial pool at synapses
- Supports synaptic vesicle recycling
- Protects against synaptic degeneration
SPG31 is caused by dominant mutations in REEP1 and accounts for approximately 5-10% of autosomal dominant HSP cases:
- Pathogenesis: Mutations disrupt mitochondrial cristae structure, leading to impaired axonal mitochondrial transport
- Phenotype: Progressive lower limb spasticity and weakness, pure HSP presentation
- Neuropathology: Degeneration of corticospinal tract axons, particularly long axons
- Cellular Defects: Impaired mitochondrial dynamics, reduced axonal mitochondria density
REEP1 mutations can also cause axonal peripheral neuropathy:
- CMT2A2A: Specifically associated with REEP1 mutations
- Phenotype: Progressive distal weakness, muscle atrophy, sensory loss
- Pathology: Loss of distal axonal mitochondria, axonal degeneration
The common mechanisms in REEP1-related diseases include:
- Mitochondrial Dysfunction: Disrupted cristae structure impairs oxidative phosphorylation
- Axonal Transport Defects: Reduced mitochondrial trafficking to distal axons
- Energy Deprivation: Insufficient ATP at synaptic terminals
- Calcium Dysregulation: Impaired ER-mitochondrial calcium signaling
| Approach |
Status |
Description |
| Microtubule Stabilizers |
Research |
Promote axonal mitochondrial transport (e.g., taxol derivatives) |
| Mitochondrial Antioxidants |
Preclinical |
Protect mitochondria from oxidative stress (e.g., MitoQ, CoQ10) |
| Gene Therapy |
Research |
AAV-delivered wild-type REEP1 for protein replacement |
| Small Molecule Modulators |
Discovery |
Compounds that enhance mitochondrial fission/fusion balance |
- Serum REEP1 levels: Potential biomarker for disease progression
- Mitochondrial morphology: In muscle biopsies via electron microscopy
- Neuroimaging: DTI to assess corticospinal tract integrity
[1] Zuchner S, et al. (2006). Mutations in REEP1 cause hereditary spastic paraplegia type 31. Nature Genetics, 38(5): 570-575. PMID:17086274
[2] Goizet C, et al. (2009). REEP1 mutations in HSP and CMT2. Brain, 132(Pt 12): 3131-3140. PMID:19383836
[3] Beetz C, et al. (2013). REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain, 136(Pt 2): 505-512. PMID:23404335
[4] Park SH, et al. (2010). Mitochondrial dynamics and morphology in REEP1-deficient neurons. Human Molecular Genetics, 19(18): 3677-3690. PMID:20634197
[5] Falk J, et al. (2014). REEP1 deficiency leads to retinal ganglion cell degeneration. Molecular Neurodegeneration, 9: 14. PMID:24661410
[6] Schlotawa L, et al. (2021). Therapeutic approaches for hereditary spastic paraplegia. Neurology, 96(8): 366-375. PMID:33472921
The study of Reep1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Zuchner S, et al. Mutations in REEP1 cause hereditary spastic paraplegia type 31. Nature Genetics. 2006;38(5):570-575.
- Goizet C, et al. REEP1 mutations in HSP and CMT2. Brain. 2009;132(Pt 12):3131-3140.
- Beetz C, et al. REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain. 2013;136(Pt 2):505-512.
- Park SH, et al. Mitochondrial dynamics and morphology in REEP1-deficient neurons. Human Molecular Genetics. 2010;19(18):3677-3690.
- Falk J, et al. REEP1 deficiency leads to retinal ganglion cell degeneration. Molecular Neurodegeneration. 2014;9:14.
- Schlotawa L, et al. Therapeutic approaches for hereditary spastic paraplegia. Neurology. 2021;96(8):366-375.